This poster, presented at E.S.PKU 2026, reports on the interim results from the APHENITY Extension Study, which evaluated long-term blood phenylalanine (Phe) control with sepiapterin treatment in people with phenylketonuria (PKU)
European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria (E.S.PKU)
The European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria (E.S.PKU) congress brings together patients, families, healthcare professionals and patient advocates from across Europe to share their knowledge, promote collaboration, and improve care for people living with PKU.
Please select the resource of interest below:
|
Congress
Topic
Type
Year
▼ Sepiapterin is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-PTC923-2500012 | September 2025
MED-ALL-PKU-2500224 | September 2026